Home › Brain Diseases › NCT04383808

Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

Who can join

Ages 21 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

1. Whole body radiation dose within the last year of less than 5000 mrem
2. Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved
3. Subjects will be at least 21 years of age
4. Subject provides written informed consent
5. Subject is deemed healthy by the PI by via self-reported questionnaire

Exclusion Criteria:

1. For patients who will be receiving a tracer injection, no known allergy to the imaging agents
2. Participant has a history of or current diagnosis of cancer
3. Participant is pregnant or nursing
4. Metallic implants (contraindicated for MRI)

About the study

The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET/MRI system using a common radiopharmaceutical.

What is being tested

• Injected radiotracer with PET Insert (diagnostic test)
• Pre-injected group with PET insert (diagnostic test)

Sponsor: Stanford University · Participants: 40 · Started: Apr 1, 2025

Contact the study team

• Paul Newswanger · Phone: (650) 736-1349

Official record on ClinicalTrials.gov — NCT04383808

Locations in the U.S.

Conditions

• Brain Diseases

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.